JNJ-77242113
janssen,protagonist therapeutics
['frontier 1', 'psoriasis', 'jnj-77242113', '$ptgx']
$ptgx a phase 2, randomized, placebo-controlled, dose-ranging study of oral jnj-77242113 for the treatment of moderate-to-severe plaque psoriasis: frontier 1 #wcd2023singapore 
L/S biotech. PhD student @UniofOxford